A Loss for Johnson & Johnson: Win for Victims: Jury Verdict in Risperdal Male Breast Trial
Updated February 24, 2015 Well that didn't take long: A Philadelphia jury decided the health care giant must pay $2.5 million in damages for failing to warn that its Risperdal antipsychotic could cause gynecomastia, which is abnormal development of breasts in males. The lawsuit was brought by...